New products and services from Samsung Electronics America, Syneron Medical, American Medical Systems, New Star, Buffalo Filter, Cook Medical, Endo International, Trimel BioPharma Metamark, and the National Comprehensive Cancer Network.
Ridgefield Park, NJ-Samsung Electronics America Inc. announced the U.S. availability of its RS80A, a high-resolution, full-featured, ultrasound system. The premium system provides fast, easy, and accurate imaging across a number of applications, including urology, according to Samsung. The company’s technology supports the RS80A’s unique S-Vision architecture complemented by S-Vue transducer performance and ClearVision digital imaging processing. The RS80A incorporates a high-resolution, 23-inch HD LED display, a 13.3-inch tilting tablet touchscreen, and a six-way motorized adjustable console.
For more information, visit www.samsung.com/ultrasound.
Roseville, CA-Syneron Medical Ltd. has signed a multi-year agreement with American Medical Systems (AMS) to supply holmium lasers for the treatment of kidney stones. The agreement furthers the partnership between AMS and New Star, a recently acquired subsidiary of Syneron, and its CoolTouch line of products. New Star’s NS3000, a holmium laser device marketed under the name StoneLight 30, recently received FDA clearance. The 30-W laser is positioned as a powerful, robust, yet compact device with the ability to treat larger stones that also provides precise control of stone breaking, dusting, and retropulsion, according to Syneron Medical.
For more information, visit www.syneron-candela.com.
Lancaster, NY-Buffalo Filter’s PlumePen Elite is a next-generation surgical plume evacuation pencil that the company says features a compact, ultra-slim, ergonomic design. It also includes an adjustable capture port, over-molded button design that helps with the prevention of sticking buttons, full-blade reveal for improved visibility at the surgical site, 360-degree swivel to allow for fluid hand movement and free range of motion, and light and flexible tubing that aids in reducing pull, hand fatigue, and wrist tension.
For more information, visit www.buffalofilter.com.
Bloomington, IN-The Perc NGage (shown) and Perc NCompass nitinol stone extractors are now available from Cook Medical. The two extractors are designed specifically to remove stones and stone fragments when physicians are removing kidney stones percutaneously. The design of the extractors mimics the original NGage and NCompass, which are indicated for ureteroscopic stone removal procedures. The different wire configurations of each extractor are useful in various scenarios. For example, the Perc NGage can grasp and release a stone, while the Perc NCompass has a 16-wire configuration.
For more information, visit www.cookmedical.com.
Dublin-Endo International plc has acquired rights to testosterone nasal gel (Natesto) from Trimel BioPharma SRL, a subsidiary of Trimel Pharmaceuticals Corp. Natesto, indicated for replacement therapy in adult males diagnosed with hypogonadism, was approved by the FDA in May 2014. Under the terms of the agreement, Endo receives exclusive commercial rights to the Natesto product in the U.S. and Mexico. In addition, Endo will collaborate on all regulatory and clinical development activities in coordination with Trimel.
For more information, visit www.endo.com.
Cambridge MA-Metamark’s laboratory in Cambridge, MA has received accreditation from the College of American Pathologists. The laboratory will be the primary location for the processing of ProMark, the newly launched, protein-based biopsy test for men with prostate cancer. ProMark provides an individualized score that helps patients and physicians determine the most appropriate treatment options for men diagnosed with prostate cancer, specifically the approximately 85% of patients with biopsy Gleason grades 3+3 or 3+4.
For more information, visit www.metamark.us.
Fort Washington, PA-The National Comprehensive Cancer Network has launched the Reimbursement Resource App, a free resource through which patients with cancer, providers, case managers, and payers can search for available reimbursement resources and patient assistance programs for multiple cancer types and supportive care indications. The app includes interfaces tailored for each of three audiences-patient or caregiver, payer or case manager, and physician or provider-through which users can search for payment programs by three categories: cancer type or supportive care indication, drug name, or reimbursement or assistance program. The app is free through the Apple Store and Google Play Store and can be found by searching “NCCN Reimbursement.”
For more information, visit www.NCCN.org.
Subscribe to Urology Times to get monthly news from the leading news source for urologists.